Regeneron Pharmaceuticals
inventory was tumbling just after the medication maker described reduced product sales of its Eylea vaccine than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(REGN) mentioned fourth-quarter gross sales of Eylea have been $1.5 billion. The consensus connect with among analysts tracked by FactSet was for $1.64 billion, while the yr-previously determine was $1.55 billion.
Regeneron Pharmaceuticals
inventory was tumbling just after the medication maker described reduced product sales of its Eylea vaccine than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(REGN) mentioned fourth-quarter gross sales of Eylea have been $1.5 billion. The consensus connect with among analysts tracked by FactSet was for $1.64 billion, while the yr-previously determine was $1.55 billion.
